Search research articles
Contact Us
Filters
Showing results (11-20 of 50) with videos related to
Page
of 5
Sort By:
Haematologica
|
May 17, 2020
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
Nyla A Heerema, Natarajan Muthusamy, Qiuhong Zhao, et al.
British Journal of Haematology
|
December 2, 2017
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor
Kerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Haematologica
|
August 30, 2023
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
Johannes Duell, Pau Abrisqueta, Marc Andre, et al.
Hematological Oncology
|
May 10, 2024
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
Kaitlin Annunzio, Subodh Bhatta, Walter Hanel, et al.
Leukemia
|
July 25, 2020
Second cancer incidence in CLL patients receiving BTK inhibitors
David A Bond, Ying Huang, James L Fisher, et al.
Oncotarget
|
April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
Timothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Blood
|
March 31, 2010
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
Erin Hertlein, Amy J Wagner, Jeffrey Jones, et al.
Blood
|
August 17, 2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Kerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Leukemia & Lymphoma
|
February 12, 2015
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma
Farrukh T Awan, Joseph M Flynn, Jeffrey A Jones, et al.
Cancer
|
March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
Jonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 50) with videos related to
Sort By:
Page
of 5
Haematologica
|
May 17, 2020
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
Nyla A Heerema, Natarajan Muthusamy, Qiuhong Zhao, et al.
British Journal of Haematology
|
December 2, 2017
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor
Kerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Haematologica
|
August 30, 2023
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
Johannes Duell, Pau Abrisqueta, Marc Andre, et al.
Hematological Oncology
|
May 10, 2024
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
Kaitlin Annunzio, Subodh Bhatta, Walter Hanel, et al.
Leukemia
|
July 25, 2020
Second cancer incidence in CLL patients receiving BTK inhibitors
David A Bond, Ying Huang, James L Fisher, et al.
Oncotarget
|
April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
Timothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Blood
|
March 31, 2010
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
Erin Hertlein, Amy J Wagner, Jeffrey Jones, et al.
Blood
|
August 17, 2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Kerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Leukemia & Lymphoma
|
February 12, 2015
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma
Farrukh T Awan, Joseph M Flynn, Jeffrey A Jones, et al.
Cancer
|
March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
Jonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.
Page
of 5